The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials
Measurable residual disease (MRD) status in chronic lymphocytic leukemia (CLL), assessed on and after treatment, correlates with increased progression-free and overall survival benefit. More recently, MRD assessment has been included in large clinical trials as a primary outcome and is increasingly...
Main Authors: | A. Fisher, H. Goradia, N. Martinez-Calle, PEM. Patten, T. Munir |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1130617/full |
Similar Items
-
Measurable Residual Disease in Chronic Lymphocytic Leukemia: Experience in Real-Life Setting with Dry Tube Flow Cytometric Method
by: Seval AKPINAR, et al.
Published: (2022-06-01) -
Measurable residual disease in chronic lymphocytic leukemia
by: Giulia Benintende, et al.
Published: (2023-02-01) -
Infections in patients with chronic lymphocytic leukemia
by: Mariana Guarana, et al.
Published: (2023-07-01) -
Meningeal involvement in chronic lymphocytic leukemia
by: S. N. Menshakova, et al.
Published: (2022-11-01) -
From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct
by: Isabel González-Gascón-y-Marín, et al.
Published: (2021-04-01)